BETA
BETA
TherapeuticsMD
TXMD46
$1.83arrow_drop_up2.23%$0.04
Penny Stock
TXMD46
$1.83
arrow_drop_up2.23%Performance History
| Key Stats | |
|---|---|
| Open | $1.83 |
| Prev. Close | $1.79 |
| EPS | -0.57 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $20.41M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.72 | 1.84 |
| 52 Week Range | 1.43 | 4.35 |
| Ratios | |
|---|---|
| EPS | -0.57 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
Correlated Companies
About TherapeuticsMD (TXMD)
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- CEO
- Headquarters
- Boca Raton
- Employees
- 1
- Exchange
- NASDAQ
Keep an eye on TherapeuticsMD
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is the market capitalization of TherapeuticsMD (TXMD)?
TherapeuticsMD (TXMD) has a market capitalization of $20.41M. The average daily trading volume is 9.44K, indicating the stock's liquidity and investor engagement.
help
What is TherapeuticsMD 's (TXMD) price per share?
The current price per share for TherapeuticsMD (TXMD) is $1.83. The stock has seen a price change of $0.04 recently, indicating a 2.23% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for TherapeuticsMD (TXMD)?
For TherapeuticsMD (TXMD), the 52-week high is $4.35, which is 137.7% from the current price. The 52-week low is $1.43, the current price is 27.97% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is TherapeuticsMD (TXMD) a growth stock?
TherapeuticsMD (TXMD) has shown an average price growth of 0.41% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying TherapeuticsMD as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is TherapeuticsMD (TXMD) stock price performance year to date (YTD)?
As of the latest data, TherapeuticsMD (TXMD) has a year-to-date price change of -21.46%. Over the past month, the stock has experienced a price change of 6.4%. Over the last three months, the change has been -1.61%. Over the past six months, the figure is -19.38%. Looking at a longer horizon, the five-year price change stands at -98.35%.
help
Is TherapeuticsMD (TXMD) a profitable company?
TherapeuticsMD (TXMD) has a net income of -$7.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 29.19% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -364.86% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.3M, although specific revenue growth data is currently not available. The gross profit is $380K. Operating income is noted at -$8.52M. Furthermore, the EBITDA is -$6.77M.
News
4/14/2023
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
11/15/2022
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
11/9/2022
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
NEWS
PENNY STOCKS
SMALL CAP
PRE-MARKET OUTLOOK
MARKETS
MOVERS
TRADING IDEAS
9/7/2022Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
NEWS
PENNY STOCKS
SMALL CAP
INTRADAY UPDATE
MARKETS
MOVERS
TRADING IDEAS
8/15/2022Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday
EARNINGSCALL-TRANSCRIPTS
8/15/2022TherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call Transcript
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.